Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years by CNBC Markets | March 31, 2025 8:24 am | US Markets The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
